Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement

Complement dependent cytotoxicity (CDC) is an important mechanism of action for monoclonal antibodies (mAb) used in the treatment of chronic lymphocytic leukemia (CLL). We hypothesized that alemtuzumab (ALM) mediated CDC would be increased by addition of ofatumumab (OFA). CLL cells from 21 previousl...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Lymphoma
Autori principali: Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K., LaPlant, Betsy R., Pavey, Emily S., Nowakowski, Grzegorz S., Zent, Clive S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058513/
https://ncbi.nlm.nih.gov/pubmed/22475085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.681657
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi